興發集團(600141.SH):擬投資43.08億元新建有機硅新材料一體化循環項目
格隆匯5月17日丨興發集團(600141.SH)公佈,公司於2021年5月17日召開十屆一次董事會,審議通過了《關於內蒙古興發科技有限公司投資新建有機硅新材料一體化循環項目的議案》,項目總投資43.08億元,建設內容:40萬噸/年有機硅單體及配套5萬噸/年草甘膦、30萬噸/年燒鹼生產裝置。
完工時間:40萬噸/年有機硅單體裝置擬於2023年6月建成投產,配套5萬噸/年草甘膦裝置擬於2022年6月建成投產,配套30萬噸/年燒鹼裝置擇機建設。
投資效益:項目全部建成投產後,年可實現銷售收入50.19億元,銷售利潤7.23億元,税後利潤4.29億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.